GRI Bio Reports 6-Week Interim Lung Function Data In Ongoing Phase 2A Study In Idiopathic Pulmonary Fibrosis
Sept 11 (Reuters) - GRI Bio Inc GRI.O:
GRI BIO REPORTS 6-WEEK INTERIM LUNG FUNCTION DATA IN ONGOING PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”)
GRI BIO INC - GRI-0621 SHOWS NO WORSENING OF FVC AT 6 WEEKS
GRI BIO INC - PHASE 2A STUDY FULLY ENROLLED; TOPLINE DATA EXPECTED Q3 2025
GRI BIO INC - NO SAFETY CONCERNS OBSERVED BY IDMC IN GRI-0621 STUDY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

Nvidia Makes First Bet on Legal AI, Invests $50 Million in Legora

POET Technologies Stock Could Still Surge in 2026, but the Bar for a Breakout Is Higher Now

Palantir Q1 2026 Earnings Preview — Is PLTR a Buy at $144?

Amazon vs. Microsoft: Which Stock Is a Better Buy for 2026 and Beyond?

Tradingkey






